FULC Slate Reverse Merger: $245M Migraine Play

Fulcrum Therapeutics (Nasdaq: FULC) is reverse-merging with Slate Medicines, a private migraine biotech, in an all-stock deal that hands Slate’s anti-PACAP/VIP pipeline a Nasdaq listing. The combined company will keep the Slate Medicines name and trade under the ticker SLTE, backed by an oversubscribed $245 million private placement. Fulcrum shares closed at $3.86 on the news.

The structure echoes the Fibrx reverse merger earlier this month: a cash-constrained public shell hands its listing to a private company with a hotter pipeline. Pre-merger Fulcrum holders will own roughly 5% of the combined entity, Slate holders 95%. Fulcrum contributes about $20.3 million in cash and pays a dividend of roughly $270 million to its shareholders ahead of closing, effectively returning most of its remaining capital.

Slate’s lead asset is SLTE-1009, a clinical-stage subcutaneous monoclonal antibody that binds both PACAP and VIP, two neuropeptides central to migraine. Slate argues a single antibody that blocks both targets should beat PACAP-only drugs on efficacy. The candidate, licensed from China’s DartsBio, was engineered for half-life extension to allow subcutaneous dosing and potential quarterly administration. Slate emerged from stealth in February 2026 with a $130 million Series A led by RA Capital, Forbion, and Foresite, and is led by CEO Gregory Oakes.

The $245 million PIPE, led by Frazier Life Sciences with Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, and Mingxin, is expected to fund operations into 2029 through a Phase 1 healthy-volunteer study and a Phase 2 dose-ranging trial in migraine patients, planned for the second half of 2027. The cash covers an ambitious jump: Slate is still pre-data, so the money has to carry the asset from healthy volunteers through proof of concept.

The market is big but competitive. CGRP-blocking migraine drugs generated about $5 billion in 2025 sales, and Lundbeck’s anti-PACAP antibody bocunebart already posted positive Phase 2b data in June. Eli Lilly’s anti-PACAP program failed and was scrapped, a reminder that PACAP-only targeting is not a sure thing. Slate’s pitch is that blocking both PACAP and VIP, plus a quarterly dosing schedule, improves on what CGRP drugs already deliver.

For Fulcrum, this is the exit after it discontinued its sickle cell drug pociredir and began exploring strategic alternatives in June. The risk is familiar: SLTE-1009 has no clinical data yet, and investors are being asked to pay for a dual-target thesis against a class with a mixed record. Watch the SLTE debut at deal close and the Phase 2 readout in H2 2027.

Source: Fulcrum–Slate Medicines merger press release